Risk Factors Update Summary

• Issuances of common stock could result in significant dilution and cause stock price to fall.
• The company deprioritized the IgAN program, discontinuing all IgAN clinical development activities in 2023.
• The company received regulatory approval for a Phase 1b clinical trial of tegoprubart in up to 24 subjects.
• Future issuances of shares of common stock were added to the risk factors.
• Plans to focus resources on kidney transplantation programs, discontinuing islet cell transplantation and deprioritizing IgAN.
• The text regarding period-to-period fluctuations in financial results was replaced with future issuances of shares of common stock.
• The company plans to evaluate tegoprubart for the treatment of IgAN, with a Phase 2 global study in twelve countries.
• The risk factor now includes the impact on insurance coverage and reimbursement of newly approved products.
• Received IND clearance for a Phase 2 BESTOW trial of tegoprubart for prevention of transplant rejection in kidney transplant recipients.
• The company entered into a collaborative research agreement with eGenesis for xenotransplantation studies.